Samandhy Cedeno

Badalona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.

Journal: Communications medicine
Published: July 18, 2025

Converging and evolving immuno-genomic routes toward immune escape in breast cancer.

Converging and evolving immuno-genomic routes toward immune escape in breast cancer.

Journal: Nature communications
Published: August 21, 2023

Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.

Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.

Journal: The Journal of infectious diseases
Published: July 05, 2022

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.

Journal: iScience
Published: June 02, 2022

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Journal: Nature medicine
Published: November 03, 2021

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.

Journal: EBioMedicine
Published: October 29, 2021

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Journal: Cell reports
Published: October 06, 2020

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study.

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study.

Journal: Frontiers in immunology
Published: July 22, 2020

Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?

Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?

Journal: Frontiers in immunology
Published: June 18, 2020

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Journal: Frontiers in immunology
Published: February 13, 2020

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

Journal: Frontiers in immunology
Published: December 08, 2019

A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection.

A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection.

Journal: Microbes and infection
Published: August 02, 2016
Showing 1-12 of 24

Last Updated: 09/26/2026